|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdel-Wahab AF, Mahmoud W and Al-Harizy
RM: Targeting glucose metabolism to suppress cancer progression:
Prospective of anti-glycolytic cancer therapy. Pharmacol Res.
150:1045112019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lebelo MT, Joubert AM and Visagie MH:
Warburg effect and its role in tumourigenesis. Arch Pharm Res.
42:833–847. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thews O and Riemann A: Tumor pH and
metastasis: A malignant process beyond hypoxia. Cancer Metastasis
Rev. 38:113–129. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jun YJ, Jang SM, Han HL, Lee KH, Jang KS
and Paik SS: Clinicopathologic significance of GLUT1 expression and
its correlation with Apaf-1 in colorectal adenocarcinomas. World J
Gastroenterol. 17:1866–1873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grabellus F, Nagarajah J, Bockisch A,
Schmid KW and Sheu SY: Glucose transporter 1 expression, tumor
proliferation, and iodine/glucose uptake in thyroid cancer with
emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med.
37:121–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo XM, Zhou SH and Fan J: Glucose
transporter-1 as a new therapeutic target in laryngeal carcinoma. J
Int Med Res. 38:1885–1892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carvalho KC, Cunha IW, Rocha RM, Ayala FR,
Cajaíba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG and Soares
FA: GLUT1 expression in malignant tumors and its use as an
immunodiagnostic marker. Clinics (Sao Paulo). 66:965–972. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan Z, Yang C, Zhang X, Zheng P and Shen
W: Expression of glucose transporter 1 and prognosis in non-small
cell lung cancer: A pooled analysis of 1665 patients. Oncotarget.
8:60954–60961. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Minami K, Saito Y, Imamura H and Okamura
A: Prognostic significance of p53, Ki-67, VEGF and Glut-1 in
resected stage I adenocarcinoma of the lung. Lung Cancer. 38:51–57.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andersen S, Eilertsen M, Donnem T,
Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Diverging
prognostic impacts of hypoxic markers according to NSCLC histology.
Lung Cancer. 72:294–302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Osugi J, Yamaura T, Muto S, Okabe N,
Matsumura Y, Hoshino M, Higuchi M, Suzuki H and Gotoh M: Prognostic
impact of the combination of glucose transporter 1 and ATP citrate
lyase in node-negative patients with non-small lung cancer. Lung
Cancer. 88:310–318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meijer TW, Schuurbiers OC, Kaanders JH,
Looijen-Salamon MG, de Geus-Oei LF, Verhagen AF, Lok J, van der
Heijden HF, Rademakers SE, Span PN and Bussink J: Differences in
metabolism between adeno- and squamous cell non-small cell lung
carcinomas: Spatial distribution and prognostic value of GLUT1 and
MCT4. Lung Cancer. 76:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang L and Deberardinis RJ: Cancer
metabolism: When more is less. Nature. 489:511–512. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo CY, Zhu Q, Tou FF, Wen XM, Kuang YK
and Hu H: The prognostic value of PKM2 and its correlation with
tumour cell PD-L1 in lung adenocarcinoma. BMC Cancer. 19:2892019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rzechonek A, Kaminska A, Mamczur P,
Drapiewski A and Budzynski W: Limited clinical significance of
dimeric form of pyruvate kinase as a diagnostic and prognostic
biomarker in non-small cell lung cancer. Adv Exp Med Biol.
955:51–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tirpe AA, Gulei D, Ciortea SM, Crivii C
and Berindan-Neagoe I: Hypoxia: Overview on hypoxia-mediated
mechanisms with a focus on the role of HIF genes. Int J Mol Sci.
20:61402019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goswami CP and Nakshatri H: PROGgeneV2:
Enhancements on the existing database. BMC Cancer. 14:9702014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang H, Xiao G, Behrens C, Schiller J,
Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A
12-gene set predicts survival benefits from adjuvant chemotherapy
in non-small cell lung cancer patients. Clin Cancer Res.
19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schuurbiers OCJ, Meijer TW, Kaanders JH,
Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, van der
Heijden EH, Oyen WJ, Visser EP, Span PN and Bussink J: Glucose
metabolism in NSCLC is histology-specific and diverges the
prognostic potential of 18FDG-PET for adenocarcinoma and squamous
cell carcinoma. J Thorac Oncol. 9:1485–1493. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan C, Yu J, Liu Y, Xu H and Wang E:
Increased NDRG1 expression is associated with advanced T stages and
poor vascularization in non-small cell lung cancer. Pathol Oncol
Res. 18:549–556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Z and Zhang H: Reprogramming of
glucose, fatty acid and amino acid metabolism for cancer
progression. Cell Mol Life Sci. 73:377–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Masoud GN and Li W: HIF-1α pathway: Role,
regulation and intervention for cancer therapy. Acta Pharm Sin B.
5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sasaki H, Shitara M, Yokota K, Hikosaka Y,
Moriyama S, Yano M and Fujii Y: Overexpression of GLUT1 correlates
with Kras mutations in lung carcinomas. Mol Med Rep. 5:599–602.
2012.PubMed/NCBI
|
|
30
|
Maki Y, Soh J, Ichimura K, Shien K,
Furukawa M, Muraoka T, Tanaka N, Ueno T, Yamamoto H, Asano H, et
al: Impact of GLUT1 and Ki-67 expression on early-stage lung
adenocarcinoma diagnosed according to a new international
multidisciplinary classification. Oncol Rep. 29:133–140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sobue T, Suzuki T, Fujimoto I, Matsuda M,
Doi O, Mori T, Furuse K, Fukuoka M, Yasumitsu T, Kuwahara O, et al:
Case-control study for lung cancer and cigarette smoking in Osaka,
Japan: Comparison with the results from Western Europe. Jpn J
Cancer Res. 85:464–473. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu P, Alves TC, Kibbey RG and Simons M:
Metabolic analysis of lymphatic endothelial cells. Methods Mol
Biol. 1846:325–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang H, Zou Y, Zhao J, Li X, Yang S, Zhou
X, Mou D, Zhong W and Cai Y: Pyruvate kinase M2 mediates glycolysis
in the lymphatic endothelial cells and promotes the progression of
lymphatic malformations. Am J Pathol. 191:204–215. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang B, Xie Z and Li B: The
clinicopathologic impacts and prognostic significance of GLUT1
expression in patients with lung cancer: A meta-analysis. Gene.
689:76–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Yang P and Li Z: The multifaceted
regulation and functions of PKM2 in tumor progression. Biochim
Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
|
|
36
|
Li L, Zhang Y, Qiao J, Yang JJ and Liu ZR:
Pyruvate kinase M2 in blood circulation facilitates tumor growth by
promoting angiogenesis. J Biol Chem. 289:25812–25821. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zahra K, Dey T, Ashish Mishra SP and
Pandey U: Pyruvate kinase M2 and cancer: The role of PKM2 in
promoting tumorigenesis. Front Oncol. 10:1592020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kubo Y, Aishima S, Tanaka Y, Shindo K,
Mizuuchi Y, Abe K, Shirabe K, Maehara Y, Honda H and Oda Y:
Different expression of glucose transporters in the progression of
intrahepatic cholangiocarcinoma. Hum Pathol. 45:1610–1617. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cerfolio RJ, Bryant AS, Ohja B and
Bartolucci AA: The maximum standardized uptake values on positron
emission tomography of a non-small cell lung cancer predict stage,
recurrence, and survival. J Thorac Cardiovasc Surg. 130:151–159.
2005. View Article : Google Scholar : PubMed/NCBI
|
